The Los Angeles Times (1/12, Adams) reports, “In a letter to the New England Journal of Medicine published Jan. 1, a Food and Drug Administration (FDA) official reported that since Fosamax (alendronate) was first marketed in 1995, 23 cases of esophageal cancer in patients taking the drug — including eight deaths — have been reported to the” FDA.
From the American Association for Justice news release.